Eclipse Life Sciences, Inc., a privately held clinical-stage biopharmaceutical company developing next-generation therapies for retinal diseases, announced...
Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113 Substantial regression was observed i...
Alentis Therapeutics and PinotBio announced they have entered into a research collaboration and licensing agreement to discover and develop next-generation...
Orum Therapeutics (“Orum” or the “Company”) (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjug...
Biopharma Boardroom speaks with Dr Anthony Bradley, Co-Founder and Chief Scientific Officer at DaltonTx, about how the company is b...
Study published in Journal of Extracellular Vesicles validates platform for new class of liquid biopsy: multiomic disease biology of living cells from ...
Results build on ONWARD3 highest complete skin clearance (54% PASI 100) at Week 48, reinforcing envudeucitinib’s potential to become a leading oral...
Results from RAPIDe-3 demonstrate that treatment with deucrictibant IR resulted in faster time to onset of symptom relief (1.28 hours) and to complete sy...
Systech, a global leader in pharmaceutical serialization and traceability, announced the availability of two new integrated packaging solutions designed to...
AJ201 (rosolutamide) is an investigational oral small molecule designed to address multiple disease mechanisms of spinal and bulbar muscular atrophy (SBM...
Joint venture between Reset Health and Pharmacy2U creates the first and only fully integrated national cardiometabolic care provider. Averly Health will...
Curaleaf International, part of Curaleaf Holdings, Inc. (TSX: CURA) in partnership with Jupiter Research LLC, announced that its Que Medical Inhalation Dev...
Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF) a biopharmaceutical company advancing innovative cancer therapies through AI-powered d...
Fenebrutinib cut relapses by 51% and 58% vs teriflunomide in Phase III RMS trials (FENhance 1 & 2) while showing a consistent, positive trend in dela...
© 2026 Biopharma Boardroom. All Rights Reserved.
